Current position

Ray Dalio’s Atricure Inc (ATRC) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares76.31KHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Atricure Inc in Q2 2021. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 76.31K shares. The latest verified filing showed: Bought 127.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 127.7% more+42.79K shares · 76.31K shares reported after the change
Filing context

Quarter-end price $27.98 · Estimated holding basis $28.22

Q1 2026
New position+33.52K shares · 33.52K shares reported
Filing context

Quarter-end price $28.53 · Estimated holding basis $28.53

Q4 2024
Sold the entire position−19.69K shares · No shares reported at quarter-end
Q3 2024
Sold 51.2% of the position−20.63K shares · 19.69K shares remained
Filing context

Quarter-end price $28.04 · Estimated holding basis $46.29

Q2 2024
Sold 12.4% of the position−5.69K shares · 40.32K shares remained
Filing context

Quarter-end price $22.77 · Estimated holding basis $46.29

Q1 2024
Bought 125.2% more+25.58K shares · 46.01K shares reported after the change
Filing context

Quarter-end price $30.42 · Estimated holding basis $46.29

Portfolio importance

How important is Atricure Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#700of 997 reported positions
Peak portfolio weight0.0%Q2 2021
Best historical rank#374Q3 2021
At peak importanceQ2 2021
ATRC
0.0%
Largest holding
5.4%
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$59.122026-09-17

Market context only; not an investor transaction price.

Latest filing quarter-end price$27.98Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$28.22Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.